250 related articles for article (PubMed ID: 31752477)
21. R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.
Steinhardt MJ; Krummenast FC; Rosenwald A; Gerhard-Hartmann E; Heidemeier A; Einsele H; Topp MS; Duell J
J Cancer Res Clin Oncol; 2022 Jan; 148(1):205-214. PubMed ID: 34085097
[TBL] [Abstract][Full Text] [Related]
22. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Eyre TA; Kirkwood AA; Wolf J; Hildyard C; Mercer C; Plaschkes H; Griffith J; Fields P; Gunawan A; Oliver R; Booth S; Martinez-Calle N; McMillan A; Bishton M; Fox CP; Collins GP; Hatton CSR
Br J Haematol; 2019 Oct; 187(2):185-194. PubMed ID: 31222719
[TBL] [Abstract][Full Text] [Related]
23. Central nervous system involvement in diffuse large B-cell lymphoma.
Yamamoto W; Tomita N; Watanabe R; Hattori Y; Nakajima Y; Hyo R; Hashimoto C; Motomura S; Ishigatsubo Y
Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301
[TBL] [Abstract][Full Text] [Related]
24. Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
Malecek MK; Petrich AM; Rozell S; Chu B; Trifilio S; Galanina N; Maurer M; Farooq U; Link BK; Nowakowski GS; Nabhan C; Ayed AO
Am J Hematol; 2017 Nov; 92(11):1156-1162. PubMed ID: 28719025
[TBL] [Abstract][Full Text] [Related]
25. Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.
Bonnet A; Bossard C; Gabellier L; Rohmer J; Laghmari O; Parrens M; Sarkozy C; Dulery R; Roland V; Llamas-Gutierrez F; Oberic L; Fornecker LM; Bounaix L; Villemagne B; Szablewski V; Choquet S; Bouabdallah K; Traverse-Glehen A; Mohty M; Sanhes L; Houot R; Gastinne T; Leux C; Le Gouill S
Cancer Med; 2022 Oct; 11(19):3602-3611. PubMed ID: 35538643
[TBL] [Abstract][Full Text] [Related]
26. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
27. Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis.
Ho G; Tan C; de Mel S; Poon L; Chan EHL; Lee J; Liu X; Chng WJ; Chee YL; Soon YY; Jeyasekharan AD
Crit Rev Oncol Hematol; 2021 Nov; 167():103507. PubMed ID: 34656744
[TBL] [Abstract][Full Text] [Related]
28. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
Eyre TA; Djebbari F; Kirkwood AA; Collins GP
Haematologica; 2020 Jul; 105(7):1914-1924. PubMed ID: 31488560
[TBL] [Abstract][Full Text] [Related]
30. Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
Zhang N; Xu D; Liu B; Shi X; Xie X; Wang Z
Int Immunopharmacol; 2022 Dec; 113(Pt A):109299. PubMed ID: 36252471
[TBL] [Abstract][Full Text] [Related]
31. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
Kumar A; Vanderplas A; LaCasce AS; Rodriguez MA; Crosby AL; Lepisto E; Czuczman MS; Nademanee A; Niland J; Gordon LI; Millenson M; Zelenetz AD; Friedberg JW; Abel GA
Cancer; 2012 Jun; 118(11):2944-51. PubMed ID: 22006274
[TBL] [Abstract][Full Text] [Related]
32. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era.
Vassilakopoulos TP; Panitsas F; Mellios Z; Apostolidis J; Michael M; Gurion R; Ferhanoglu B; Hatzimichael E; Karakatsanis S; Dimou M; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Giatra H; Kanellias N; Sayyed A; Tadmor T; Akay OM; Angelopoulou MK; Horowitz N; Bakiri M; Pangalis GA; Panayiotidis P; Papageorgiou SG
Hematol Oncol; 2023 Feb; 41(1):97-107. PubMed ID: 36314897
[TBL] [Abstract][Full Text] [Related]
33. [Current achievements and future perspectives in the research on intravascular large B-cell lymphoma].
Shimada K
Rinsho Ketsueki; 2021; 62(6):631-640. PubMed ID: 34219091
[TBL] [Abstract][Full Text] [Related]
34. Current progress and future perspectives of research on intravascular large B-cell lymphoma.
Shimada K; Kiyoi H
Cancer Sci; 2021 Oct; 112(10):3953-3961. PubMed ID: 34327781
[TBL] [Abstract][Full Text] [Related]
35. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
36. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.
Feugier P; Virion JM; Tilly H; Haioun C; Marit G; Macro M; Bordessoule D; Recher C; Blanc M; Molina T; Lederlin P; Coiffier B
Ann Oncol; 2004 Jan; 15(1):129-33. PubMed ID: 14679132
[TBL] [Abstract][Full Text] [Related]
37. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
38. Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma.
Yi JH; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
Cytokine; 2020 May; 129():155048. PubMed ID: 32135464
[TBL] [Abstract][Full Text] [Related]
39. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
40. [Intravascular Large B-cell Lymphoma: a Clinical Analysis of 17 Cases].
Yang JJ; Chen XC; Tang Y; Shen K; Xie LP; Liu T
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):145-147. PubMed ID: 29737107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
